{"downloaded": true, "htmlmade": false, "full": {"id": "29573207", "source": "MED", "pmid": "29573207", "pmcid": "PMC5943466", "fullTextIdList": {"fullTextId": "PMC5943466"}, "doi": "10.1002/cam4.1388", "title": "An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.", "authorString": "Vacirca JL, Chan A, Mezei K, Adoo CS, P\u00e1pai Z, McGregor K, Okera M, Horv\u00e1th Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Rostom M, Bhat G, Choi MR, Reddy G, Tedesco KL, Agajanian R, L\u00e1ng I, Schwartzberg LS.", "authorList": {"author": [{"fullName": "Vacirca JL", "firstName": "Jeffrey L", "lastName": "Vacirca", "initials": "JL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "New York Cancer Specialists, East Setauket, New York."}}}, {"fullName": "Chan A", "firstName": "Arlene", "lastName": "Chan", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia."}}}, {"fullName": "Mezei K", "firstName": "Kl\u00e1ra", "lastName": "Mezei", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Szabolcs-Szatm\u00e1r Bereg County Hospital and University Teaching Hospital, Ny\u00edregyh\u00e1za, Hungary."}}}, {"fullName": "Adoo CS", "firstName": "Clarence S", "lastName": "Adoo", "initials": "CS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Arizona Center for Cancer Care, Glendale, Arizona."}}}, {"fullName": "P\u00e1pai Z", "firstName": "Zsuzsanna", "lastName": "P\u00e1pai", "initials": "Z", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "State Health Center, Budapest, Hungary."}}}, {"fullName": "McGregor K", "firstName": "Kimberly", "lastName": "McGregor", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Samaritan Hematology and Oncology Associates, Corvalis, Oregon."}}}, {"fullName": "Okera M", "firstName": "Meena", "lastName": "Okera", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Adelaide Cancer Centre, Kurralta Park, South Australia, Australia."}}}, {"fullName": "Horv\u00e1th Z", "firstName": "Zsolt", "lastName": "Horv\u00e1th", "initials": "Z", "authorId": {"@type": "ORCID", "#text": "0000-0002-5376-7737"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Debrecen, Debrecen, Hungary."}}}, {"fullName": "Landherr L", "firstName": "L\u00e1szl\u00f3", "lastName": "Landherr", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Uzsoki Hospital, Budapest, Hungary."}}}, {"fullName": "Hanslik J", "firstName": "Jerzy", "lastName": "Hanslik", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Szpital Rejonowy Dzienny Oddzial Chemioterapii, Raciborzu, Poland."}}}, {"fullName": "Hager SJ", "firstName": "Steven J", "lastName": "Hager", "initials": "SJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "California Cancer Associates for Research and Excellence, Fresno, California."}}}, {"fullName": "Ibrahim EN", "firstName": "Emad N", "lastName": "Ibrahim", "initials": "EN", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Emad Ibrahim MD, Inc., Redlands, California."}}}, {"fullName": "Rostom M", "firstName": "Makharadze", "lastName": "Rostom", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Cancer Center of Adjara Autonomous Republic, Batumi, Georgia."}}}, {"fullName": "Bhat G", "firstName": "Gajanan", "lastName": "Bhat", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Spectrum Pharmaceuticals, Irvine, California."}}}, {"fullName": "Choi MR", "firstName": "Mi Rim", "lastName": "Choi", "initials": "MR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Spectrum Pharmaceuticals, Irvine, California."}}}, {"fullName": "Reddy G", "firstName": "Guru", "lastName": "Reddy", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Spectrum Pharmaceuticals, Irvine, California."}}}, {"fullName": "Tedesco KL", "firstName": "Karen L", "lastName": "Tedesco", "initials": "KL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, New York."}}}, {"fullName": "Agajanian R", "firstName": "Richy", "lastName": "Agajanian", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "The Oncology Institute of Hope and Innovation, Downey, California."}}}, {"fullName": "L\u00e1ng I", "firstName": "Istv\u00e1n", "lastName": "L\u00e1ng", "initials": "I", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "National Institute of Oncology, Budapest, Hungary."}}}, {"fullName": "Schwartzberg LS", "firstName": "Lee S", "lastName": "Schwartzberg", "initials": "LS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "West Cancer Center, Memphis, Tennessee."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-5376-7737"}}, "dataLinksTagsList": {"dataLinkstag": "supporting_data"}, "journalInfo": {"issue": "5", "volume": "7", "journalIssueId": "2682512", "dateOfPublication": "2018 May", "monthOfPublication": "5", "yearOfPublication": "2018", "printPublicationDate": "2018-05-01", "journal": {"title": "Cancer medicine", "ISOAbbreviation": "Cancer Med", "medlineAbbreviation": "Cancer Med", "NLMid": "101595310", "ISSN": "2045-7634", "ESSN": "2045-7634"}}, "pubYear": "2018", "pageInfo": "1660-1669", "abstractText": "This randomized, open-label, active-controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long-acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficacy endpoint was duration of severe neutropenia (DSN) during the first cycle of treatment. Patients who were candidates for adjuvant/neoadjuvant TC chemotherapy were eligible for participation. TC was administered on Day 1, followed by 45, 135, or 270\u00a0\u03bcg/kg Rolontis or 6\u00a0mg pegfilgrastim on Day 2. Complete blood counts were monitored daily when the absolute neutrophil count (ANC) fell to <1.5\u00a0\u00d7\u00a0109 /L. Up to four cycles of TC were investigated. The difference in DSN (time from ANC <0.5\u00a0\u00d7\u00a0109 /L to ANC recovery \u22652.0\u00a0\u00d7\u00a0109 /L) between the Rolontis and pegfilgrastim groups was -0.28\u00a0days (confidence interval [CI]: -0.56, -0.06) at 270\u00a0\u03bcg/kg, 0.14\u00a0days (CI: -0.28, 0.64) at 135\u00a0\u03bcg/kg, and 0.72\u00a0days (CI: 0.19, 1.27) at 45\u00a0\u03bcg/kg. Noninferiority to pegfilgrastim was demonstrated at 135\u00a0\u03bcg/kg (P\u00a0=\u00a00.002) and 270\u00a0\u03bcg/kg (P\u00a0<\u00a0.001), with superiority demonstrated at 270\u00a0\u03bcg/kg (0.03\u00a0days; P\u00a0=\u00a00.023). The most common treatment-related adverse events (AEs) were bone pain, myalgia, arthralgia, back pain, and elevated white blood cell counts, with similar incidences across groups. All doses of Rolontis were well tolerated, and no new or significant treatment-related toxicities were observed. In Cycle 1, Rolontis demonstrated noninferiority at the 135\u00a0\u03bcg/kg dose and statistical superiority in DSN at the 270\u00a0\u03bcg/kg dose when compared to pegfilgrastim.", "affiliation": "New York Cancer Specialists, East Setauket, New York.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Controlled Clinical Trial", "Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Breast Neoplasms", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Neutropenia", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}, {"abbreviation": "EP", "qualifierName": "epidemiology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Polyethylene Glycols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Cyclophosphamide", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Filgrastim", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "AA", "qualifierName": "analogs & derivatives", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Drug Administration Schedule"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Docetaxel", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}]}, "keywordList": {"keyword": ["Breast cancer", "Neutropenia", "Rolontis", "Eflapegrastim"]}, "chemicalList": {"chemical": [{"name": "Antineoplastic Agents", "registryNumber": "0"}, {"name": "docetaxel", "registryNumber": "15H5577CQD"}, {"name": "Cyclophosphamide", "registryNumber": "8N3DW7272P"}, {"name": "Filgrastim", "registryNumber": "PVI5M0M1GW"}, {"name": "pegfilgrastim", "registryNumber": "3A58010674"}, {"name": "Polyethylene Glycols", "registryNumber": "3WJQ0SDW1A"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1002/cam4.1388"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5943466"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5943466?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "2", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-09-06", "dateOfCreation": "2018-03-25", "firstIndexDate": "2018-03-25", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2019-09-06", "electronicPublicationDate": "2018-03-23", "firstPublicationDate": "2018-03-23"}, "htmllinks": "https://europepmc.org/articles/PMC5943466", "abstract": "This randomized, open-label, active-controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long-acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficacy endpoint was duration of severe neutropenia (DSN) during the first cycle of treatment. Patients who were candidates for adjuvant/neoadjuvant TC chemotherapy were eligible for participation. TC was administered on Day 1, followed by 45, 135, or 270\u00a0\u03bcg/kg Rolontis or 6\u00a0mg pegfilgrastim on Day 2. Complete blood counts were monitored daily when the absolute neutrophil count (ANC) fell to <1.5\u00a0\u00d7\u00a0109 /L. Up to four cycles of TC were investigated. The difference in DSN (time from ANC <0.5\u00a0\u00d7\u00a0109 /L to ANC recovery \u22652.0\u00a0\u00d7\u00a0109 /L) between the Rolontis and pegfilgrastim groups was -0.28\u00a0days (confidence interval [CI]: -0.56, -0.06) at 270\u00a0\u03bcg/kg, 0.14\u00a0days (CI: -0.28, 0.64) at 135\u00a0\u03bcg/kg, and 0.72\u00a0days (CI: 0.19, 1.27) at 45\u00a0\u03bcg/kg. Noninferiority to pegfilgrastim was demonstrated at 135\u00a0\u03bcg/kg (P\u00a0=\u00a00.002) and 270\u00a0\u03bcg/kg (P\u00a0<\u00a0.001), with superiority demonstrated at 270\u00a0\u03bcg/kg (0.03\u00a0days; P\u00a0=\u00a00.023). The most common treatment-related adverse events (AEs) were bone pain, myalgia, arthralgia, back pain, and elevated white blood cell counts, with similar incidences across groups. All doses of Rolontis were well tolerated, and no new or significant treatment-related toxicities were observed. In Cycle 1, Rolontis demonstrated noninferiority at the 135\u00a0\u03bcg/kg dose and statistical superiority in DSN at the 270\u00a0\u03bcg/kg dose when compared to pegfilgrastim.", "Keywords": ["Breast cancer", "Neutropenia", "Rolontis", "Eflapegrastim"], "pdflinks": "https://europepmc.org/articles/PMC5943466?pdf=render", "journaltitle": "Cancer medicine", "authorinfo": ["Vacirca JL", "Chan A", "Mezei K", "Adoo CS", "P\u00e1pai Z", "McGregor K", "Okera M", "Horv\u00e1th Z", "Landherr L", "Hanslik J", "Hager SJ", "Ibrahim EN", "Rostom M", "Bhat G", "Choi MR", "Reddy G", "Tedesco KL", "Agajanian R", "L\u00e1ng I", "Schwartzberg LS"], "title": "An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer."}